{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:48:09Z","timestamp":1790200089223,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Castleman Awareness and Research Effort\/Castleman Disease Collaborative Network"},{"DOI":"10.13039\/100006154","name":"Lauri Strauss Leukemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL128239"],"award-info":[{"award-number":["R01 HL128239"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009784","name":"Starr Foundation","doi-asserted-by":"publisher","award":["I8-A8-075"],"award-info":[{"award-number":["I8-A8-075"]}],"id":[{"id":"10.13039\/100009784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010304","name":"Pershing Square Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,4,9]]},"DOI":"10.1038\/s41388-020-1204-9","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T19:02:33Z","timestamp":1581534153000},"page":"3218-3225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Genetic basis for iMCD-TAFRO"],"prefix":"10.1038","volume":"39","author":[{"given":"Akihide","family":"Yoshimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Trippett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Pichardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyeon","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Sigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"1204_CR1","doi-asserted-by":"crossref","unstructured":"Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53:57\u201361.","DOI":"10.3960\/jslrt.53.57"},{"key":"1204_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3960\/jslrt.53.95","volume":"53","author":"M Inoue","year":"2013","unstructured":"Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hematop. 2013;53:95\u20139.","journal-title":"J Clin Exp Hematop"},{"key":"1204_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24242","volume":"91","author":"N Iwaki","year":"2016","unstructured":"Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220\u20136.","journal-title":"Am J Hematol"},{"key":"1204_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep42316","volume":"7","author":"N Iwaki","year":"2017","unstructured":"Iwaki N, Gion Y, Kondo E, Kawano M, Masunari T, Moro H, et al. Elevated serum interferon gamma-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep. 2017;7:42316.","journal-title":"Sci Rep."},{"key":"1204_CR5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ajh.25123","volume":"93","author":"SK Pierson","year":"2018","unstructured":"Pierson SK, Stonestrom AJ, Shilling D, Ruth J, Nabel CS, Singh A, et al. Plasma proteomics identifies a \u2018chemokine storm\u2019 in idiopathic multicentric Castleman disease. Am J Hematol. 2018;93:902\u201312.","journal-title":"Am J Hematol"},{"key":"1204_CR6","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","volume":"3","author":"AY Liu","year":"2016","unstructured":"Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman\u2019s disease: a systematic literature review. Lancet Haematol. 2016;3:e163\u201375.","journal-title":"Lancet Haematol"},{"key":"1204_CR7","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","volume":"129","author":"DC Fajgenbaum","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8\u2013negative\/idiopathic multicentric Castleman disease. Blood. 2017;129:1646\u201357.","journal-title":"Blood"},{"key":"1204_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/modpathol.2017.160","volume":"31","author":"N Ozkaya","year":"2018","unstructured":"Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 2018;31:581\u201397.","journal-title":"Mod Pathol"},{"key":"1204_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/13793","volume":"23","author":"WJ Song","year":"1999","unstructured":"Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166\u201375.","journal-title":"Nat Genet"},{"key":"1204_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/annonc\/mdw066","volume":"27","author":"A Yoshimi","year":"2016","unstructured":"Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, et al. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. Ann Oncol. 2016;27:887\u201395.","journal-title":"Ann Oncol"},{"key":"1204_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/bloodadvances.2017009654","volume":"2","author":"A Nagy","year":"2018","unstructured":"Nagy A, Bhaduri A, Shahmarvand N, Shahryari J, Zehnder JL, Warnke RA, et al. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. Blood Adv. 2018;2:481\u201391.","journal-title":"Blood Adv"},{"key":"1204_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400\u20134.","journal-title":"Nature"},{"key":"1204_CR13","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"1204_CR14","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1182\/bloodadvances.2018023911","volume":"2","author":"TS Baker","year":"2018","unstructured":"Baker TS, Gambino KJ, Schriefer L, Lim JY, Steinberg KM, Fajgenbaum DC, et al. A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. Blood Adv. 2018;2:2959\u201363.","journal-title":"Blood Adv"},{"key":"1204_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.ajhg.2010.10.028","volume":"87","author":"A Bolze","year":"2010","unstructured":"Bolze A, Byun M, McDonald D, Morgan NV, Abhyankar A, Premkumar L, et al. Whole-exome-sequencing-based discovery of human FADD deficiency. Am J Hum Genet. 2010;87:873\u201381.","journal-title":"Am J Hum Genet"},{"key":"1204_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251\u201364.","journal-title":"J Mol Diagn"},{"key":"1204_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-019-1618-0","volume":"574","author":"A Yoshimi","year":"2019","unstructured":"Yoshimi A, Lin KT, Wiseman DH, Rahman MA, Pastore A, Wang B, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574:273\u20137.","journal-title":"Nature"},{"key":"1204_CR18","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1182\/blood-2009-12-261602","volume":"117","author":"A Yoshimi","year":"2011","unstructured":"Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, et al. Evi1 represses PTEN expression and activates PI3K\/AKT\/mTOR via interactions with polycomb proteins. Blood. 2011;117:3617\u201328.","journal-title":"Blood"},{"key":"1204_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1182\/blood.V99.4.1364","volume":"99","author":"J Michaud","year":"2002","unstructured":"Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, et al. In vitro analyses of known and novel RUNX1\/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364\u201372.","journal-title":"Blood"},{"key":"1204_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","volume":"14","author":"F Wang","year":"2012","unstructured":"Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14:22\u20139.","journal-title":"J Mol Diagn"},{"key":"1204_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41375-018-0323-6","volume":"33","author":"Z Li","year":"2019","unstructured":"Li Z, Lan X, Li C, Zhang Y, Wang Y, Xue W, et al. Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia. 2019;33:1035\u20138.","journal-title":"Leukemia"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1204-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1204-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1204-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:20:15Z","timestamp":1684617615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-1204-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":21,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,4,9]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-1204-9","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"9 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DCF receives research funding from EUSA Pharma for the ACCELERATE Registry (formerly sponsored by Janssen Pharmaceuticals). AD has received personal fees from Roche, Corvus Pharmaceuticals, Physicians\u2019 Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, and Novartis and research grants from National Cancer Institute, Roche. OA-W has served as a consultant for H3 Biomedicine, Foundation Medicine Inc., Merck, and Janssen and serves on the scientific advisory board of Envisagenics Inc.; OA-W has received personal speaking fees from Daiichi Sankyo. OA-W has received prior research funding from H3 Biomedicine unrelated to the current paper. OA-W is an inventor on a provisional patent application submitted by Fred Hutchinson Cancer Research Center that covers BRD9 activation in cancer. WX has received research support from Stemline therapeutics. Other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}